Prostate Cancer

Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients

Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients

By

Weight loss associated with bariatric surgery could reduce risk of hormone-related cancers, but an increased risk for colorectal cancer was seen in patients who underwent gastric bypass.

USPSTF Updates Guidelines for PSA-Based Screening for Prostate Cancer in Older Men

USPSTF Updates Guidelines for PSA-Based Screening for Prostate Cancer in Older Men

By

In updating its 2012 recommendations, the US Preventive Services Task Force changes its stance on PSA-based screening for prostate cancer in men older than 50. The new guidelines advocate for a patient-physician discussion of the benefits of testing vs the potential harms.

Overall Survival Benefit With Prostate Cancer Vaccine Not Duplicated in Phase 3 Trial

Overall Survival Benefit With Prostate Cancer Vaccine Not Duplicated in Phase 3 Trial

By

Latest findings do not confirm an overall survival (OS) benefit found in a previous randomized phase 2 trial.

No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer

No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer

By

The addition of mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy did not increase survival among patients with high-risk prostate cancer.

Smoking During Primary Therapy Worsens Oncologic Outcomes in Prostate Cancer

Smoking During Primary Therapy Worsens Oncologic Outcomes in Prostate Cancer

By

A meta-analysis of 11 studies revealed the effects of smoking outcomes of primary radical radiotherapy or radical prostatectomy for prostate cancer.

ADT Affects Sexual Function, Intimacy in Early Prostate Cancer Treatment

ADT Affects Sexual Function, Intimacy in Early Prostate Cancer Treatment

By

Researchers report on a study investigating effects of ADT on prostate cancer health-related quality of life, sexual function, sexual bother, and mood for patients with prostate cancer and their partners.

Drinking Wine in Moderation Does Not Appear to Impact Prostate Cancer Risk

Drinking Wine in Moderation Does Not Appear to Impact Prostate Cancer Risk

Interestingly, red and white wine to not affect prostate cancer risk the same way.

USPSTF: Decision to Undergo PSA Screening Should Be Individual

USPSTF: Decision to Undergo PSA Screening Should Be Individual

The decision to undergo periodic PSA screening for prostate cancer should be an individual one for men aged 55 to 69 years, according to the recommendation statement.

Lower Disease-Specific Mortality Seen With Early Detection of Prostate Cancer

Lower Disease-Specific Mortality Seen With Early Detection of Prostate Cancer

By

In an analysis of data from the SEER program, researchers determined that early detection of prostate cancer has let to an improvement in the number of men presenting with metastatic prostate cancer.

Challenges of Shared Decision Making in Prostate Cancer Screening

Challenges of Shared Decision Making in Prostate Cancer Screening

By

A review of shared decision making with men about undergoing PSA testing revealed that although full SDM discussions are increasing, variations in whether these discussions occur and how much information is shared still exist.

Long-term Prostate Cancer Risk Reduction Seen With Finasteride 

Long-term Prostate Cancer Risk Reduction Seen With Finasteride 

By

Finasteride recipients had a 21.1% decreased risk of prostate cancer compared with placebo recipients, researchers found.

PSA Screening Increases Prostate Cancer Detection, No Significant Difference in Mortality

PSA Screening Increases Prostate Cancer Detection, No Significant Difference in Mortality

By

Researchers conducted a randomized clinical study of men to determine the impact of PSA screening on prostate cancer detection and mortality.

Following False-Positive Results, Patients More Likely to Have Future Cancer Screenings

Following False-Positive Results, Patients More Likely to Have Future Cancer Screenings

The researchers found that the choice to undergo future screenings appeared to be influenced by previous false-positive results for both men and women.

Taxane Acute Pain Syndrome in Cancer Therapy: Occurrence, Impact on Quality of Life

Taxane Acute Pain Syndrome in Cancer Therapy: Occurrence, Impact on Quality of Life

By

Results of a prospective study of patients with breast or prostate cancer demonstrate the impact of taxane-based chemotherapy on quality of life.

Increased Monitoring Increases Cost, Not Quality of Care or Survival, in Prostate Cancer

Increased Monitoring Increases Cost, Not Quality of Care or Survival, in Prostate Cancer

By

In an evaluation of SEER-Medicare data, researchers sought to determine the benefits of extreme use of monitoring in patients with metastatic prostate cancer at the end of life on survival outcomes, quality of life, and costs.

Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance

Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance

By

ADT recipients reported worse subjective sleep disturbance, researchers found.

Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC

Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC

By

According to the FDA, the drug approval is the first to use the end point of metastasis-free survival.

Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer

Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer

Aggressive therapy does not appear to be more beneficial than conservative androgen deprivation therapy alone, according to a study.

Single PSA screening increases prostate cancer detection but does not change mortality

1. In this randomized controlled trial, men who were screened with a single PSA test had higher diagnoses of prostate cancer than those who were unscreened. 2. There was no difference in mortality between the two groups. Evidence Rating Level: 1 (Excellent) Study Rundown: In the era of prostate-specific antigen (PSA) screening, there has been []

Single Screening for PSA Levels Does Not Improve Survival in Prostate Cancer

Single Screening for PSA Levels Does Not Improve Survival in Prostate Cancer

By

Researchers sought to determine the effect single PSA testing had on prostate cancer diagnosis, mortality, and all-cause mortality.

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

By

At $225 million per system, the precision of proton beam radiotherapy is not necessarily overshadowing its high costs. Yet ongoing studies seek to determine how this technology fits into current treatment regimens for prostate, breast, and other cancers.

Travel Distance to Prostate Cancer Treatment Influences Treatment Choice 

Travel Distance to Prostate Cancer Treatment Influences Treatment Choice 

By

Long-distance travel was more strongly associated with definitive prostate SBRT use, researchers found.

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

By

SPARTAN phase 3 study shows that apalutamide prolongs metastasis-free survival and time to symptomatic progression compared with placebo among men with nonmetastatic CRPC.

Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers

Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers

Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.

Daily IGRT Regimen for Prostate Cancer Improves Rectal Toxicity, Not OS

Daily IGRT Regimen for Prostate Cancer Improves Rectal Toxicity, Not OS

By

Researchers present findings of a comparison of daily image-guided radiotherapy (IGRT) vs a weekly regimen in patients with N0 localized prostate cancer at the 2018 GU Cancers Symposium.

Active Surveillance, Repeat Biopsies Not Linked to Post Prostatectomy Complications

Active Surveillance, Repeat Biopsies Not Linked to Post Prostatectomy Complications

By

Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.

Adjuvant Radiotherapy Found Superior to Early-Salvage RT in Prostate Cancer

Adjuvant Radiotherapy Found Superior to Early-Salvage RT in Prostate Cancer

Propensity score-matched study compared adjuvant radiotherapy with surveillance and early-salvage radiotherapy after prostatectomy in men with prostate cancer.

Priority Review of New Drug Application Granted to Apalutamide for CRPC

Priority Review of New Drug Application Granted to Apalutamide for CRPC

By

Data from the phase 3 SPARTAN trial prompted the FDA's Priority Review designation for apalutamide.

Active Surveillance Required Following Prostate Cancer Focal Ablation

Active Surveillance Required Following Prostate Cancer Focal Ablation

In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.

Testosterone Therapy May Lower Prostate Cancer Incidence

Testosterone Therapy May Lower Prostate Cancer Incidence

By

Hypogonadal men who received testosterone replacement therapy had a lower incidence of prostate cancer than those who did not, and their cancers were less severe.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs